Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.

Authors: Wangtrakuldee, Phumvadee; Adeniji, Adegoke O; Zang, Tianzhu; Duan, Ling; Khatri, Buddha; Twenter, Barry M; Estrada, Michelle A; Higgins, Tyler F; Winkler, Jeffrey D; Penning, Trevor M

Published In J Steroid Biochem Mol Biol, (2019 09)

Abstract: Drugs used for the treatment of castration resistant prostate cancer (CRPC) include Abiraterone acetate (Zytiga®) and Enzalutamide (XTANDI®). However, these drugs provide clinical benefit in metastatic disease for only a brief period before drug resistance emerges. One mechanism of drug resistance involves the overexpression of type 5 17-β-hydroxysteroid dehydrogenase (aldo-keto reductase 1C3 or AKR1C3), a major enzyme responsible for the formation of intratumoral androgens that activate the androgen receptor (AR). 3-((4-Nitronaphthalen-1-yl)amino)benzoic acid 1 is a "first-in-class" AKR1C3 competitive inhibitor and AR antagonist. Compound 1 was compared in a battery of in vitro studies with structurally related N-naphthyl-aminobenzoates, and AKR1C3 targeted therapeutics e.g. GTx-560 and ASP9521, as well as with R-bicalutamide, enzalutamide and abiraterone acetate. Compound 1 was the only naphthyl derivative that was a selective AKR1C3 inhibitor and AR antagonist in direct competitive binding assays and in AR driven reporter gene assays. GTx-560 displayed weak activity as a direct AR antagonist but had high potency in the AR reporter gene assay consistent with its ability to inhibit the co-activator function of AKR1C3. By contrast ASP9521 did not act as either an AR antagonist or block AR reporter gene activity. Compound 1 was the only compound that showed comparable potency to inhibit AKR1C3 and act as a direct AR antagonist. Compound 1 blocked the formation of testosterone in LNCaP-AKR1C3 cells, and the expression of PSA driven by the AKR1C3 substrate (4-androstene-3,17-dione) and by an AR agonist, 5α-dihydrotestosterone consistent with its bifunctional role. Compound 1 blocked the nuclear translocation of the AR at similar concentrations to enzalutamide and caused disappearance of the AR from cell lysates. R-biaclutamide and enzalutamide inhibited AKR1C3 at concentrations 200x greater than compound 1, suggesting that its bifunctionality can be explained by a shared pharmacophore that can be optimized.

PubMed ID: 30641225 Exiting the NIEHS site

MeSH Terms: Aldo-Keto Reductase Family 1 Member C3/antagonists & inhibitors*; Androgen Receptor Antagonists/chemistry; Androgen Receptor Antagonists/pharmacology*; Apoptosis; Benzoates/chemistry; Benzoates/pharmacology*; Cell Proliferation; Enzyme Inhibitors/chemistry; Enzyme Inhibitors/pharmacology*; Humans; Male; Naphthalenes/chemistry; Naphthalenes/pharmacology*; Prostatic Neoplasms, Castration-Resistant/drug therapy*; Prostatic Neoplasms, Castration-Resistant/enzymology; Prostatic Neoplasms, Castration-Resistant/pathology; Receptors, Androgen/chemistry*; Tumor Cells, Cultured

to Top